Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention

G. Caocci, O. Mulas, M. Bonifacio, E. Abruzzese, S. Galimberti, E.M. Orlandi, A. Iurlo, M. Annunziata, L. Luciano, F. Castagnetti, A. Gozzini, F. Stagno, G. Binotto, P. Pregno, F. Albano, B. Martino, C. Fozza, L. Scaffidi, M.M. Trawinska, C. BaratèC. Elena, D. Cattaneo, E. Scalzulli, G. La Nasa, R. Foà, M. Breccia

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)124-127
Number of pages4
JournalInternational Journal of Cardiology
Volume288
DOIs
Publication statusPublished - 2019

Keywords

  • Chronic myeloid leukemia
  • Recurrent arterial occlusive event
  • Secondary prophylaxis
  • antithrombocytic agent
  • bosutinib
  • dasatinib
  • hydroxymethylglutaryl coenzyme A reductase inhibitor
  • nilotinib
  • ponatinib
  • adult
  • aged
  • anticoagulant therapy
  • Article
  • cancer chemotherapy
  • cardiovascular risk
  • chronic myeloid leukemia
  • cohort analysis
  • human
  • incidence
  • major clinical study
  • peripheral occlusive artery disease
  • priority journal
  • recurrent disease
  • secondary prevention

Cite this

Caocci, G., Mulas, O., Bonifacio, M., Abruzzese, E., Galimberti, S., Orlandi, E. M., Iurlo, A., Annunziata, M., Luciano, L., Castagnetti, F., Gozzini, A., Stagno, F., Binotto, G., Pregno, P., Albano, F., Martino, B., Fozza, C., Scaffidi, L., Trawinska, M. M., ... Breccia, M. (2019). Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention. International Journal of Cardiology, 288, 124-127. https://doi.org/10.1016/j.ijcard.2019.04.051